P1617: A PHASE 1 STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF A PEGYLATED-RECOMBINANT HUMAN COAGULATION FACTOR VIII-FC FUSION PROTEIN WITH HALF-LIFE IN PATIENTS WITH SEVERE HEMOPHILIA A
Feng Xue,
Yun Chen Chen,
Jing Sun,
Shuxia Guo,
Qing Wen,
Chongyuan Xu,
Renchi Yang
Affiliations
Feng Xue
1 Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Blood Diseases, Tianjin, China
Yun Chen Chen
2 Jinan central hospita, Department of Hematology, Jinan, China
Jing Sun
3 Nanfang Hospital of Southern Medical University, Department of Hematology, Guangzhou, China
Shuxia Guo
4 Zhengzhou People’s Hospital, Department of Hematology, Zhengzhou, China
Qing Wen
5 Jinan central hospita, Office of Drug Clinical Trial Institutions, Jinan, China
Chongyuan Xu
6 Nanfang Hospital of Southern Medical University, Office of Drug Clinical Trial Institutions, Guangzhou, China
Renchi Yang
7 Chinese Academy of Medical Sciences & Peking Union Medical College, Thrombosis And Hemostasis Diagnosis And Treatment Center, Tianjin, China
